Phase 1 and preclinical profiling of ESM‐HDAC391, a myeloid‐targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia

AIMS: To improve the tolerability and therapeutic application of histone deacetylase inhibitors (HDACi), by application of an esterase‐sensitive motif (ESM), to target pharmacological activity directly to mononuclear myeloid cells expressing the processing enzyme carboxylesterase‐1 (CES1). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Furze, Rebecca C., Molnar, Judit, Parr, Nigel J., Ahmad, Faiz, Henry, Yvette, Howe, David, Singh, Rajendra, Toal, Martin, Bassil, Anna K., Bernard, Sharon G., Davis, Robert P., Gibson, Adele, Maller, N. Claire, Sharp, Catriona, Tough, David F., Prinjha, Rab K., Lewis, Huw D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796293/
https://www.ncbi.nlm.nih.gov/pubmed/35655123
http://dx.doi.org/10.1111/bcp.15428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796293/
https://www.ncbi.nlm.nih.gov/pubmed/35655123
http://dx.doi.org/10.1111/bcp.15428

Ejemplares similares